<table>
<thead>
<tr>
<th>項目</th>
<th>内容</th>
</tr>
</thead>
<tbody>
<tr>
<td>タイトル</td>
<td>Successful Treatment with Bosentan for Pulmonary Hypertension and Reduced Peripheral Circulation in Juvenile Systemic Sclerosis</td>
</tr>
<tr>
<td>著者</td>
<td>Shimizu, Masaki; Hashida, Yoko; Ueno, Kazuyuki; Yokoyama, Tadafumi; Nakayama, Yuko; Saito, Takekatsu; Ohta, Kunio; Takehara, Kazuhiko; Yachie, Akihiro</td>
</tr>
<tr>
<td>引用</td>
<td>Pediatric Cardiology, 32(7): 1040-1042</td>
</tr>
<tr>
<td>発行日</td>
<td>2011-10</td>
</tr>
<tr>
<td>テイプ</td>
<td>Journal Article</td>
</tr>
<tr>
<td>リンク</td>
<td><a href="http://hdl.handle.net/2297/29205">http://hdl.handle.net/2297/29205</a></td>
</tr>
<tr>
<td>右</td>
<td><a href="http://dspace.lib.kanazawa-u.ac.jp/dspace/">http://dspace.lib.kanazawa-u.ac.jp/dspace/</a></td>
</tr>
</tbody>
</table>

KURAに登録されているコンテンツの著作権は、執筆者、出版社（学協会）などに有します。KURAに登録されているコンテンツの利用については、著作権法に規定されている私的使用や引用などの範囲内で行ってください。著作権法に規定されている私的使用や引用などの範囲を超える利用を行う場合には、著作権者の許諾を得てください。ただし、著作権者から著作権等管理事業者（学術著作権協会、日本著作出版権管理システムなど）に権利委託されているコンテンツの利用手続については、各著作権等管理事業者に確認してください。
Successful treatment with bosentan for pulmonary hypertension and reduced peripheral circulation in juvenile systemic sclerosis

Shimizu M¹, Hashida Y¹, Ueno K¹, Yokoyama T¹, Nakayama Y¹, Saito T¹, Ohta K¹, Takehara K², Yachie A¹

¹Department of Pediatrics, School of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan
²Department of Dermatology, School of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan

Correspondence to: Masaki Shimizu, MD, PhD
Department of Pediatrics, School of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, 13-1 Takaramachi, Kanazawa 920-8641, Japan
Tel: +81-76-265-2314; Fax: +81-76-262-1866
E-mail: shimizum@staff.kanazawa-u.ac.jp

Key Words: bosentan, juvenile systemic sclerosis, pulmonary hypertension
Short title: Bosentan for juvenile SSc-related PAH
Abstract

Pulmonary arterial hypertension (PAH) when associated with systemic sclerosis (SSc) (SSc-PAH) is one of the leading causes of mortality and is found in 10%–15% of adult patients with SSc. The ET receptor antagonist named bosentan has been shown to be effective in the treatment of adult patients with SSc-PAH. Furthermore, it has been shown that bosentan ameliorates decreased skin perfusion and digital ulceration secondary to SSc. However, the effectiveness and safety of bosentan for treatment of juvenile SSc still remains unclear. We describe a case of juvenile SSc-PAH successfully treated with bosentan. The present case shows that bosentan ameliorated PAH and peripheral circulation as evaluated by cold stress thermography. No bosentan-related adverse events such as liver dysfunction were observed. Prospective randomized trials are required to validate the effectiveness of bosentan for patients with juvenile SSc; however, bosentan may be useful for the management of patients with juvenile SSc.
Introduction

Pulmonary arterial hypertension (PAH) when associated with systemic sclerosis (SSc) (SSc-PAH) is one of the leading causes of mortality and is found in 10%–15% of adult patients with SSc [2]. SSc-PAH is less frequent in juvenile cases, occurring in only 7.0%–8.7% of cases [4,8]. Plasma endothelin (ET)-1 levels are increased in patients with SSc, suggesting that ET-1 may be crucial in SSc [9]. The ET receptor antagonist named bosentan has been shown to be effective in the treatment of adult patients with SSc-PAH [2,7]. Furthermore, it has been shown that bosentan ameliorates decreased skin perfusion and digital ulceration secondary to SSc [5,6]. A previous report showed that bosentan was effective for treatment of children with primary and secondary PAH [3]. However, the effectiveness and safety of bosentan for treatment of juvenile SSc still remains unclear. Here we describe a case of juvenile SSc-PAH successfully treated with bosentan and beraprost.

Case report

A 11-year-old girl had a 1-year history of Raynaud’s phenomenon and skin sclerosis of the hands, forearms, legs and face. She visited a local hospital for arthralgia of her knees. Physical examination confirmed skin sclerosis of the entire body. Furthermore, skin biopsy revealed an increase in thickened collagen fibres in the dermis and diagnosis of juvenile SSc was confirmed. Treatment with prednisolone was initiated; however, skin sclerosis did not improve, and she developed shortness of breath 10 months later. SSc-PAH was suspected and she was admitted to our hospital. On admission, her height was 149 cm and body weight was 37.8 kg. Physical examination revealed skin sclerosis of the
entire body with a score of 29 points according to the modified Rodnan total skin thickness score (TSS). In addition, diffuse pigmentation on her neck and trunk as well as multiple digital pitting scars were observed. Nailfold capillaroscopy demonstrated reduced capillary density with dilated and giant capillaries, some microhemorrhages and a few avascular areas highly suggestive of SSc. High-resolution CT of the lungs did not demonstrate any pathological findings, whereas, ventilation/perfusion scans showed negative results. Lung function tests revealed a predicted forced vital capacity of 66.8% and a predicted diffusing capacity for carbon monoxide of 51.5%. Echocardiography showed a tricuspid pressure gradient of 46.1 mmHg and an estimated right ventricular systolic pressure of 65 mmHg. Her 6-minute walk distance was 322 m, indicating a decreased exercise capacity. Cardiac catheter examination at rest showed a mean pulmonary arterial pressure of 41 mmHg, which met the criteria of PAH. Serum ET-1 level was significantly increased (2.9 pg/ml; in age matched healthy controls; median, 0.9; range, 0.34–1.8). She was prescribed 62.5 mg/day bosentan and 60 μg/day beraprost for PAH and peripheral circulatory insufficiency including digital ulceration and Raynaud’s phenomenon. After 1 week, bosentan was increased to 125 mg/day. After bosentan therapy for 2 weeks, her estimated right ventricular systolic pressure by echocardiography decreased to 38 mmHg. Finally, bosentan was increased to 250 mg/day and beraprost to 120 μg/day. In addition to bosentan and beraprost, she was treated with six doses of monthly steroid pulse therapy (methylprednisolone 1000 mg/day, 3 days) and monthly cyclophosphamide pulse therapy (cyclophosphamide 500 mg/m²) followed by daily prednisolone (20 mg/day) and
mizoribine (150 mg/day). After these treatments, her 6-minute walk distance increased to 488 m and cardiac catheter examination showed a mean pulmonary arterial pressure of 18 mmHg. The decrease in skin temperature of the hands also improved (Figure). Furthermore, three doses of steroid and cyclophosphamide pulse therapy every 2 months were also added. Exacerbation of PAH was absent, and TSS improved to 17 points 1 year after initiation of these treatments. No bosentan-related adverse events were observed in the patient.

**Discussion**

ET-1 is a potent mitogenic factor mainly produced by endothelial cells and exerts its biological activity by interacting with two cell membrane-bound receptors, ET-A and ET-B, expressed on endothelial cells, smooth muscle cells and fibroblasts [1]. ET-1 is a potent vasoconstrictor that stimulates synthesis and accumulation of extracellular matrix proteins by fibroblasts and smooth muscle cells.

Plasma ET-1 levels are increased in patients with SSc, suggesting that it plays a key role in pathogenesis of SSc vascular diseases [9]. Bosentan has been shown to be effective for the treatment of patients with SSc-PAH [2,7]. Recently, it has been shown that bosentan also ameliorates decreased skin perfusion and digital ulceration secondary to SSc [5,6]. These effects may be mediated through vasodilatory and antifibrotic effects, indicating that these agents may be attractive potential disease modifying agents for SSc.

However, its effectiveness and safety for patients with juvenile SSc-PAH still remains unclear. The present case shows that the combination therapy with
bosentan and beraprost ameliorated PAH and peripheral circulation as evaluated by cold stress thermography. No bosentan-related adverse events such as liver dysfunction were observed. Prospective randomized trials are required to validate the effectiveness of bosentan for patients with juvenile SSc; however, bosentan may be useful for the management of patients with juvenile SSc.

Disclosure statement: The authors have declared no conflicts of interest.
References


**Figure legend**

Thermal images of the hands 12 min after cold stress. (left, before treatment; right, 6 months after the initiation of treatment)

The dysfunctional cutaneous blood flow in response to cold stimuli was improved after bosentan therapy, indicating bosentan ameliorated peripheral circulation.